Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

BACKGROUND: In the BRIM-3 trial, vemurafenib was associated with risk reduction versus dacarbazine of both death and progression in patients with advanced BRAF(V600) mutation-positive melanoma. We present an extended follow-up analysis of the total population and in the BRAF(V600E) and BRAF(V600K) m...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Lancet Oncol
Auteurs principaux: McArthur, Grant A, Chapman, Paul B, Robert, Caroline, Larkin, James, Haanen, John B, Dummer, Reinhard, Ribas, Antoni, Hogg, David, Hamid, Omid, Ascierto, Paolo A, Garbe, Claus, Testori, Alessandro, Maio, Michele, Lorigan, Paul, Lebbé, Celeste, Jouary, Thomas, Schadendorf, Dirk, O’Day, Stephen J, Kirkwood, John M., Eggermont, Alexander M, Dréno, Brigitte, Sosman, Jeffrey A, Flaherty, Keith T, Yin, Ming, Caro, Ivor, Cheng, Suzanne, Trunzer, Kerstin, Hauschild, Axel
Format: Artigo
Langue:Inglês
Publié: 2014
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4382632/
https://ncbi.nlm.nih.gov/pubmed/24508103
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(14)70012-9
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires